Clinical targets Precision Biologics is advancing monoclonal antibodies with tumor-specific targets, including NEO-102 and NEO-201, with ongoing clinical trials. Opportunities exist to discuss partnering, co-development, or licensing of these candidates to accelerate clinical programs or expand into new solid tumor indications.

AML focus Recent preclinical findings and AACR presentations highlight a potential AML target and AML CAR-NK exploration. This creates a sales hook for collaborations around novel cellular therapies, companion diagnostics, or supportive care platforms tailored to AML research and translational work.

Clinical stage As a small clinical-stage biotech with revenue in the sub‑$10M range, there is a market opportunity to engage in sponsored research, CRO partnerships, or technology licensing deals with larger biopharma seeking late-stage or near-term asset acceleration.

Therapeutic breadth A focus on tumor-specific glycans targets and ADCs against solid tumors positions the company for conversations around diagnostic tools, biomarker development, companion diagnostics, and platform integration to support patient stratification and trial design.

Industry engagement Active participation in major conferences (AACR, SITC, Festival of Biologics) signals readiness for partner outreach at events; leverage speaking engagements and preclinical/clinical data disclosures to initiate conversations on collaboration, co-development, or investment opportunities.